All proteomic data files are available from the PRIDE database (accession number PXD015375).

Introduction {#sec001}
============

Biomarkers are sought as measurable indicators of pathological processes and for treatment monitoring. Extracellular vesicles (EVs) contain a rich and multifaceted cargo of proteins, metabolites, lipids and nucleic acids for biomarker discovery, and therefore EVs are an excellent source of potential biomarkers. Although EVs can be isolated from all body fluids and from tissues, blood provides the richest source of EVs. Blood-borne EVs are a heterogeneous population originating from blood cells, endothelial cells, and for example in cancer patients from tumor cells \[[@pone.0236439.ref001]\]. Therefore, blood EVs may well serve as biomarkers of multiple diseases, either by their concentration or by a selection of molecules derived from their biochemical composition. So far, the majority of EV biomarker studies have concentrated on the discovery of cancer biomarkers \[[@pone.0236439.ref002]\], closely followed by biomarkers for cardiovascular diseases \[[@pone.0236439.ref003]\]. Plasma and serum samples offer in the form of liquid biopsy a relatively non-invasive means to detect disease-related biomarkers making them an optimal target for studies using large study cohorts and biobanks. Unfortunately, most of the currently available biobank samples have not been collected with EVs in mind. Although some confounders of sample uniformity such as anticoagulation, agitation and delay in processing (causing *ex vivo* platelet activation followed by vesiculation) are becoming better acknowledged, currently many preanalytical steps remain unaddressed in a systematic way \[[@pone.0236439.ref004], [@pone.0236439.ref005]\]. Recently, the International Society of Extracellular Vesicles (ISEV) standardization taskforce has realized the urgency of standardizing blood sample collection and generated harmonization initiatives for the field \[[@pone.0236439.ref006]\].

So far, only a few studies have addressed the effect of anticoagulation--or its absence i.e. serum---on the resulting EV population. The seminal study of George et al. demonstrated that the concentration of "platelet microparticles", isolated by centrifugation at 35 000 x g, were higher in serum than in plasma anticoagulated by acid citrate dextrose (ACD), which was attributed to platelet activation during clot formation \[[@pone.0236439.ref007]\]. In the study of György et al., ACD was shown to be superior in comparison to citrate in preventing artefactual platelet activation and vesiculation during blood collection \[[@pone.0236439.ref005]\]. However, there are no studies yet on the effect of anticoagulants on the molecular composition of blood-borne EVs. Therefore, we studied EVs isolated from blood anticoagulated with the three most commonly used anticoagulants and serum by contemporary EV analytics and following the latest recommendations regarding blood handling \[[@pone.0236439.ref006], [@pone.0236439.ref008]\].

In pharmaceutics, nanoparticles (NPs) are developed for drug delivery solutions (DDS). Due to their fast elimination from the body, synthetic NP and their protein corona have recently been under intensive investigation \[[@pone.0236439.ref009]--[@pone.0236439.ref011]\]. In addition to DDS applications, NP corona has also been suggested to be a future diagnostic tool for e.g. cancer diagnostics \[[@pone.0236439.ref012]--[@pone.0236439.ref014]\]. Previous studies have shown that the protein corona of NPs can be divided into a hard and a soft part, depending on the binding affinities of the associating proteins \[[@pone.0236439.ref015]--[@pone.0236439.ref017]\]. Proteins that bind directly to the surface of the NPs with high affinity, are considered to constitute the hard corona, and proteins that bind to other proteins via weak protein-protein interactions, constitute the soft corona \[[@pone.0236439.ref018]\]. The corona of various NPs has been studied in detail, and a shared "core"proteome has been established, which comprises lipoproteins, complement and coagulation proteins, and immunoglobulins \[[@pone.0236439.ref019]--[@pone.0236439.ref022]\]. In the present study we compared our proteomics results to NP protein corona studies.

Materials and methods {#sec002}
=====================

Preparation of plasma and serum {#sec003}
-------------------------------

Blood samples were obtained from healthy, fasting volunteers and collected into ACD-A (Vacuette \#455055, Greiner Bio-One, Kremsmünster, Austria), citrate (Vacuette \#455322, Greiner Bio-One), serum (BD \#369032, BD Biosciences, Franklin Lakes, USA) and EDTA (K2F, BD \#368861, BD Biosciences) tubes by a protocol approved by the ethical board of University of Helsinki. Volunteers had not used any medication for the previous 7 days and their informed consent was obtained according to the declaration of Helsinki. Study samples were collected twice in Helsinki (set I and II) and once in Budapest (set III), the latter to perform fluorescence size exclusion chromatography (Flu-SEC). The average age of the donors in set I was 45 years (range 27--55), 32 years (range 18--51 years) in set II, and 30 years (range 25--36) in set III. Majority of the volunteers were females (80%, 70%, and 67%). Serum, and ACD, citrate and EDTA plasma were obtained during the same blood collection, 2 x 4 mL or 10 mL for each plasma/serum type using 18G needle and tourniquet that was released immediately after the venipuncture, followed by gentle end-over-end mixing 10 times. Blood samples were processed within 30 minutes of sampling to obtain plasma, while serum was allowed to clot for 30 minutes at room temperature (RT) prior centrifugation. Samples for set I and II were centrifuged twice at 2500 × g for 15 minutes at RT (5804R, Eppendorf AG, Hamburg, Germany). For the set III, platelet-free plasma and serum was prepared by centrifuging twice at 2500 × g for 15 minutes at RT (NF 800R, RA 200 swing-out rotor, Nüve, Ankara, Turkey). For the sample sets I and II, equal volumes of individual donors' plasma/serum were combined into a pool of each anticoagulant and serum after the second centrifugation. Pooled plasma/serum samples were analyzed with Coulter T-540 counter (version 3F, Beckman Coulter, Brea, USA) for remnant cell counts, and used for experiments directly without freezing. For the set III, individual donors' samples were kept separate for the Flu-SEC analysis. The details of the workflow are provided in a ([S1 Table](#pone.0236439.s003){ref-type="supplementary-material"}).

Isolation of EVs {#sec004}
----------------

EVs from set I and II were isolated by ultracentrifugation as follows: pooled plasma (ACD, citrate and EDTA), and serum samples were diluted 1:1 with PBS and centrifuged at 110 000 × g~max~ for 90 minutes at 4˚C (k-factor 190.2, Type 50.2 Ti, Optima-LE 80K, Beckman Coulter). The supernatant was discarded, and the pellets were resuspended in 20 mL PBS followed by re-centrifugation. The final pellet was suspended in 250 μl PBS, aliquoted to Protein LoBind Tubes (Eppendorf AG) and stored at 4˚C overnight for further analysis, except for TEM and proteomics for which samples were frozen at -80˚C. For the set III, platelet-free plasma and serum were purified by SEC on a 3.5 mL gravity column filled with Sepharose CL-2B gel (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). One mL platelet-free plasma/serum was loaded on the column, the flow through was discarded and purified EVs were eluted with 1 mL PBS buffer.

We have submitted all relevant data of our experiments to the EV-TRACK knowledgebase \[[@pone.0236439.ref023]\] (<http://evtrack.org/>, ID: EV190060).

Flow cytometry analysis {#sec005}
-----------------------

Apogee A50 micro flow cytometer (ApogeeFlow, Hertfordshire, UK) equipped with 405 nm and 488 nm lasers and 525/50 and 575/30 filters was used for measuring EVs. Logarithmic scale and peak height were used. Event level below 100 events/s with 1.5 μL/minute flow rate and 150 mbar pressure was considered acceptable for background. Three washing cycles were performed between the samples. Flow rate was adjusted between 1.5--4.5 μL/minute to keep average event rates below 3000 events/s. All isolated EV samples were diluted 1:20 to obtain \~1\*10^9^ particles/mL and 50 μL was labelled (in technical triplicates) with anti- CD61-PE (clone VI-PL2, BD Biosciences, 1:25) and anti-CD235a-FITC (clone 11E4B-7-6, BD Biosciences, 1:25), matching isotype antibodies at same dilutions, or with Annexin V--Alexa488 (Invitrogen, Carlsbad, USA, 1:20) in the presence of 5 mM CaCl~2~. Labelling was done for 1 hour at room temperature in the dark. Before analysis, the isolated EV samples were further diluted 1:5. Statistical analysis was conducted using Tukey´s multiple comparison test.

Size exclusion chromatography with on-line fluorescence detection (Flu-SEC) {#sec006}
---------------------------------------------------------------------------

Flu-SEC was used to quantify the amount of platelet-derived (CD61+) EVs in serum, and ACD-, citrate- and EDTA-plasma as described earlier \[[@pone.0236439.ref024]\]. EVs were separated from soluble proteins with the Sepharose CL-2B cross-linked agarose gel (GE Healthcare Bio-Sciences AB). Four μL anti-CD61-PE (clone VI-PL2, 6 μg/mL, BioLegend, USA) was used to label platelet-derived EVs (technical triplicates) in 100 μL of SEC-isolated plasma/serum. Labelling was performed for 30 minutes at 37 ˚C. Ten μL of labeled sample was injected into a Jasco HPLC system (Jasco, Tokyo, Japan) consisting of a PU-2089 pump with a UV-2075 UV/Vis detector and a FP-2020 fluorescence detector controlled by the Chromnav software v. 1.17.02. Tricorn 5/200 glass columns (GE Healthcare Bio-Sciences AB) were packed with Sepharose CL-2B (GE Healthcare Bio-Sciences AB), and the eluent of 1 ml of PBS with a flow rate of 0.5 mL/minute. The fluorescence chromatograms were collected at excitation and emission wavelength corresponding to PE fluorochrome (565/578 nm), and the area under the curve (AUC) of the EV-peak was used to quantify the amount of platelet-derived EVs in the various plasma and serum samples. Statistical analysis was conducted using Tukey´s multiple comparison test.

Nanoparticle tracking analysis (NTA) {#sec007}
------------------------------------

Particle concentration and size distribution were determined with the NTA instrument LM14C (NanoSight LTD., London, UK) equipped with blue (404 nm, 70 mW) laser and sCMOS camera. Settings for data acquisition were: camera level 14, SOP Standard Measurement, autosettings off, polydispersity medium, reproducibility high, and acquisition time 3x 60 sec. The sample dilution was done to 0.1 μm filtered buffer pre-checked for absence of particles. Each sample was diluted to optimal 40--100 particles/frame concentration for measurement. Data were analyzed with NanoSight NTA 3.0 software with the following settings: auto background subtraction/blur/minimum track length, and detection threshold 5.

Electron microscopy {#sec008}
-------------------

Negative staining of whole mounted EV samples was performed as described \[[@pone.0236439.ref025]\]. Briefly, EVs were loaded on 200 mesh grids, fixed with 2% PFA, stained with 2% neutral uranyl acetate, embedded in methyl cellulose uranyl acetate mixture (1.8/0.4%) and viewed with Tecnai 12 (FEI Company, Eindhoven, The Netherland) at 80 kV.

SDS-PAGE and Western blot analysis {#sec009}
----------------------------------

Total of 5\*10^10^ particles of all samples were prepared with 6x Laemmli sample buffer with 10% β-mercaptoethanol and run on 4--20% gradient SDS-PAGE (Mini-Protean TGX Precast protein gel, Bio-Rad, Hercules, USA). For Western blot analysis, proteins were transferred to PVDF membrane (Immobilon-P, Merck Millipore, Burlington, USA) at 200 mA for 90 minutes using wet transfer. Nonspecific binding was blocked by with 3% BSA in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 1 hour followed by primary antibody incubation anti-TSG101 (Clone 51/TSG101 BD Biosciences, 1:500), anti-CD41 (clone SZ22, Beckman Coulter, 1:2000), or anti-CD9 (clone C-4, Santa Cruz Biotechnology, Dallas, USA, 1:500) overnight at 4˚C. The membranes were washed three times with TBST followed by incubation with horseradish peroxidase--conjugated anti-mouse secondary antibody in dilution 1:3000 (GE Healthcare Bio-Sciences AB). After washing, the signal was detected using Bio-Rad Clarity Western ECL Substrate (Bio-Rad) and imaged using LAS3000 imaging system (Fuji, Minato, Japan).

Mass spectrometry and data analysis {#sec010}
-----------------------------------

EV pellets corresponding to 100 μg of total protein were adjusted to 25mM Tris, 75mM NaCl; pH 7.5 and applied to 50 μL of albumin depletion resin slurry (Pierce, Thermo Scientific, Rockform, USA) previously washed with same buffer. Flow through and three washes were collected by centrifugation and deemed to be albumin-depleted EV proteins. The protein concentration was measured by bicinchonic acid assay kit (Thermo Fisher Scientific) for the total protein concentration. Equal amount of protein for each sample was dried in speed vacuum (Savant, Thermo Fisher Scientific), and then dissolved in 6 M urea and 100 mM Tris-HCl (pH 7.4). Reconstitution was performed with 10 mM of dithiothreitol (DTT) for 60 minutes at RT, and thereafter 30mM iodoacetamide for 60 minutes in the dark at RT. Protein digestion was performed with trypsin (18 hour at 37°C) after the consumption of abundant iodoacetamide (30 mM DTT, 60 minutes at RT) and 1:10 dilution with high-purity Milli-Q water (Millipore, Billerica, USA). Finally, the samples were cleaned up with C18 spin columns, and dried in speed vacuum following the dissolution in 0.1% formic acid containing 12.5 fmol Hi3 peptide mixture (Waters Corporation, Beverly, USA) per μl. All procedures were performed according to the manufacturer's instructions. Liquid chromatography: Four microlitre samples corresponding to 1.4 μg of total protein were injected to the ultra-performance liquid chromatography (UPLC) system (Waters Corporation) (Distler et al, 2014). TRIZAIC nanoTile 85 μm x 100mm HSS-T3u wTRAP was applied as a separating device before mass spectrometry (MS). After loading and trapping, the samples were washed for 2 minutes at 8.0 μL/minute with 1% buffer B. The analytical gradient was used as follows: 0--1 minute 1% B; at 2 minutes 5% B; at 65 minutes 30% B; at 78 minutes 50% B; at 80 minutes 85% B; at 83 minutes 85% B; at 84 minutes 1% B; and at 90 minutes 1% B with 450 nL/minute. Buffer A consists of 0.1% formic acid in water and buffer B of 0.1% formic acid in acetonitrile (Sigma-Aldrich). The data was acquired with UDMSE with Synapt G2-S UDMS (Waters Corporation, Billerica, MA) including ion mobility spectroscopy (IMS). The data range was 100--2000m/z, scan time 1 s, IMS wave velocity 650ms^1^. Calibration was performed by Glu1- fibrinopeptide B MS2 fragments and Glu1- fibrinopeptide B precursor ion, used during the acquisitions as a lock mass. Progenesis QI for proteomics software (Version 3, Nonlinear Dynamics) was used for processing of raw files. Peptide identification was run with Uniprot human FASTA sequences (UniprotKB Release 2015_09, 20205 sequence entries), and label-free protein quantification performed with Hi-N method (Protein Lynx Global Server) (Silva et al, 2006). The samples were spiked with 12.5 fmol/μL of CLPB_ECOLI (P63285, ClpB protein) peptides (Hi3 E. Coli Standard, Waters). Digesting reagent was trypsin and 2 miss cleavages were allowed. The peptide identification parameters were: fixed modification of cysteine (carbamidomethyl) and variable modification of methionine (oxidation). The peptide error tolerance was set to maximally 10 ppm and the false discovery rate limited to less than 1% and default values (in Progenesis QI for Proteomics) were used for the rest of the parameters. The quantified proteins in all comparisons were compared by ANOVA on a protein-to-protein basis and their expression levels were considered significantly different, if ANOVA p-value was less than 0.05. Principal component analysis (PCA), offering the visualization of the main axes of variation in the data groups, was performed by Progenesis QI for proteomics.

Statistics {#sec011}
----------

Statistical analysis of the flu-SEC experiment was performed by using Prism 8 (GraphPad Software, LLC, USA). One-way ANOVA test was performed without pairing and assuming Gaussian distribution and equal variance followed by Tukey multiple comparisons test with 95% confidence interval. Saphiro-Wilk test was used to test normal distribution, while the Brown--Forsythe test was used for the equality of group variances. Statistical analysis of flow cytometry and proteomics experiments was performed with IBM SPSS version 24 (IBM Corp., Armonk, USA, Released 2016). The data was tested for normality using Saphiro-Wilk test, after which Kruskall-Wallis non-parametric test was used followed by post-hoc Dunn test. Pearson correlation test was used to examine whether there were correlations between proteins analyzed by proteomics. The level of significance was set at *p* ≤ 0.05 in all experiments.

Data repository {#sec012}
---------------

The raw files were converted with MSConvert (ProteoWizard) to mzML-files. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaino et al 2014) partner repository with the dataset identifier PXD015375.

Results {#sec013}
=======

General characterization of EVs derived from ACD-, citrate- and EDTA-anticoagulated plasma and serum {#sec014}
----------------------------------------------------------------------------------------------------

In this study, we investigated how different anticoagulants and clotting affect the characteristics of blood-derived EVs. To avoid contamination with any residual platelets and/or residual platelets generating artificial EVs, all samples were centrifuged within 30 minutes after blood collection at 2500 × g 15 minutes (twice) as recommended previously \[[@pone.0236439.ref004], [@pone.0236439.ref006], [@pone.0236439.ref026]\]. Little or no residual platelets were detected in the samples ([S1A Fig](#pone.0236439.s002){ref-type="supplementary-material"}). Particle concentrations and size distributions were determined with NTA, and the vesicle morphology in samples was confirmed with TEM. The concentrations of particles calculated per original sample volume of the different plasmas or serum were not statistically different in blood collection set I (*p* = 0.631), but in set II, some variation was found in EV concentrations between serum and anticoagulated samples (*p* = 0.001; [S1B Fig](#pone.0236439.s002){ref-type="supplementary-material"}). Statistical testing for size distribution of EVs was performed for set II which had three technical replicates, but essentially similar data was also obtained from samples of set I with duplicate samples. The analysis revealed statistically significant differences when measured by bins of size classes. The significant increase of particle counts was seen with serum-derived EVs that differed from ACD, citrate and EDTA plasma--derived EVs in size classes 0--100 nm (*p* = 0.002 (ACD), *p* = 0.001 (citrate), *p* = 0.023 (EDTA) and 101--200 nm *p* = 0.044 (ACD) ([S1C Fig](#pone.0236439.s002){ref-type="supplementary-material"}). By TEM, all EVs irrespective of plasma or serum source had a similar morphology typically attributed to EVs ([S1D Fig](#pone.0236439.s002){ref-type="supplementary-material"}). To investigate the protein content of EVs, equal particle numbers based on NTA were loaded into SDS-PAGE gels. The overall protein patterns were similar in the ACD- and citrate-derived EV samples, whereas the protein bands from EDTA- and serum-derived EVs showed visible differences ([S1E Fig](#pone.0236439.s002){ref-type="supplementary-material"}). In contrast, typical EV-marker proteins as TSG101 and CD9 were detected at comparable levels when analyzed by Western blotting ([S1F Fig](#pone.0236439.s002){ref-type="supplementary-material"}).

Serum and citrate plasma contain increased numbers of platelet-derived EVs compared to ACD and EDTA plasma samples {#sec015}
------------------------------------------------------------------------------------------------------------------

In a seminal study of George et al. \[[@pone.0236439.ref007]\], serum was shown to contain more microparticles i.e. large EVs than ACD plasma. This prompted us to investigate this claim anew with contemporary analytical methods: EV-dedicated flow cytometry (Apogee 50), flu-SEC and Western blotting. EVs of different plasma and serum samples isolated by ultracentrifugation and normalized by particle numbers based on NTA, were analyzed with flow cytometry by anti-CD61 and -CD235a labelling to compare platelet and erythrocyte derived EV proportions in plasma and serum, respectively. There were less CD235a+ EVs compared to CD61+ EVs in all the samples irrespective of the anticoagulant used ([Fig 1A](#pone.0236439.g001){ref-type="fig"}). In contrast, more CD61+ events were detected in the serum samples compared to the ACD (*p* = 0.006) and EDTA (*p* = 0.001) samples, and although there was a similar trend with the citrate sample, it was not statistically significant. Statistical testing was performed for set II which had three technical replicates, but essentially similar data was also obtained from samples of set I with duplicate samples. Annexin V binding to EVs was analyzed to yield information about phosphatidylserine (PS) expression relevant for procoagulant activity. Staining with (fluorescently-labelled) annexin V was low in all plasma-derived EV samples compared to serum EVs ([Fig 1A](#pone.0236439.g001){ref-type="fig"}). Statistical analysis showed significant differences ([S2 Table](#pone.0236439.s004){ref-type="supplementary-material"}) between serum and ACD, citrate, and EDTA EVs (*p* = 0.003, *p* = 0.013, *p* = 0.006, respectively).

![Flow cytometry, fluorescence size exclusion chromatography, and Western blot of extracellular vesicles isolated from ACD-, citrate-, and EDTA-plasma and serum samples.\
A) Representative images of the Apogee flow cytometry analysis with anti-CD61-PE, anti-CD235-FITC and annexin V-FITC, respectively, B)Box blots show the average of events/μl (n = 3) for the labelled EVs isolated from plasma and serum samples. For the platelet marker CD61, significant increases in events were detected for serum and citrate-anticoagulated plasma EVs. In contrast, similar concentrations of erythrocyte (CD235a) EVs were present in plasma and serum. Serum EVs bound more a Annexin V per EVs compared to plasma EVs, C) representative chromatograms of plasma- and serum-derived EVs labelled with anti-CD61-PE and characterized with fluorescent size exclusion chromatography (n = 3). EVs were eluted with the void volume of the column at 2.8 min retention time, and the peak at 6.35 min retention time corresponded to the unbound antibody. D) The area under the curve values of the first peak were correlated with the amount of CD61+ EVs in plasma and serum samples. E) probing with anti-CD41 of the Western blots of the plasma and serum -derived EVs to detect platelet-derived EVs (TSG101 and CD9 are shown in [S1 Fig](#pone.0236439.s002){ref-type="supplementary-material"}). Each lane was loaded with a comparable number of particles based on NTA. Asterisks (\*) indicates *p* \< 0.05.](pone.0236439.g001){#pone.0236439.g001}

In sample set III, the plasma and serum samples were labelled with anti-CD61 followed by flu-SEC ([Fig 1B](#pone.0236439.g001){ref-type="fig"}). Comparison of the chromatograms of the plasma samples with that of the serum sample demonstrated that the concentration of CD61+ EVs was significantly increased in the serum samples compared to ACD, EDTA and citrate plasma (all *p*\<0.001; [S3 Table](#pone.0236439.s005){ref-type="supplementary-material"}), even up to 40-fold compared to EDTA. While there was no difference in the concentration of CD61+ EVs between the EDTA- and ACD plasma samples, citrate-anticoagulated plasma also had an increased number of CD61+ EVs compared to EDTA (p = 0.046).

When equal particle numbers were loaded on Western blot and probed with anti-CD41 to detect the platelet glycoprotein IIb, the strongest CD41 signal was in the serum-derived EVs, followed by the EVs from citrate plasma, whereas in the ACD- and EDTA-derived EVs the band intensities were equal ([Fig 1C](#pone.0236439.g001){ref-type="fig"}). The Western blot, Apogee flow cytometry and Flu-SEC results confirmed a high concentration of platelet-derived EVs in serum and citrate plasma compared to the ACD- and EDTA-plasma samples. Finally, also proteomics confirmed an increase in the presence of CD41 protein in serum and EDTA plasma--derived EV samples compared to ACD and citrate plasma -derived EVs (p = 0.04) in the quantitative proteomics of albumin-depleted samples ([Fig 1D](#pone.0236439.g001){ref-type="fig"}).

Protein cargo of the EV corona is modified by anticoagulation or its absence {#sec016}
----------------------------------------------------------------------------

Intrigued by the observations of the different protein bands in the SDS gel of the isolated EVs ([S1E Fig](#pone.0236439.s002){ref-type="supplementary-material"}), we performed a quantitative proteomic analysis for both albumin-depleted EVs and non-albumin-depleted EVs isolated from ACD-, citrate-, and EDTA-plasma and serum samples. In total, 225 proteins were detected from the albumin-depleted and 165 from the non-depleted EV samples with mass spectrometry Since all identified and quantified proteins ([S4 Table](#pone.0236439.s006){ref-type="supplementary-material"}) from the non-albumin depleted samples (n = 91 out of 165) were present in the list of albumin-depleted samples (n = 138 out of 225), we focused on the albumin-depleted proteome. Abundances of the EV proteins were used to perform principal component analysis (PCA). PCA is available in the Progenesis QI for proteomics---software package. It is an unsupervised method to determine relations between the samples and here we directly used the imported mass spectrometry data of the reliable proteins identified with two or more unique peptides. The principal axes of abundance variation are calculated by the software from protein abundances in the samples. When two or more unique peptide -containing proteins with *p*≤0.05 ANOVA were plotted in PCA, there was a complete separation of the samples into four separate groups according to anticoagulation/coagulation ([Fig 2](#pone.0236439.g002){ref-type="fig"}). The Pearson's correlation coefficiency was calculated for the 138 proteins. A threshold for the p-value was set to 0.05 to define statistical significance. More than 80% of protein pairs were positively or negatively correlated ([S5 Table](#pone.0236439.s007){ref-type="supplementary-material"}).

![Principal component analysis (PCA) of protein quantification data with two or more unique peptide -containing proteins with ANOVA significance p≤0.05.\
Green: citrate; blue: ACD; red: EDTA; yellow: serum. Each sample was run in triplicates.](pone.0236439.g002){#pone.0236439.g002}

The differences in the EV proteomes from plasma and serum samples were quantitative. A gene ontology analysis was conducted with the FunRich analysis tool \[[@pone.0236439.ref027]\] using human genome as background. Of the 138 proteins, 107 were mapped for molecular function, cellular component and biological process GO terms. The GO terms with *p*-value ≤0.05 (Holm-Bonferroni corrected) are shown in [Fig 3](#pone.0236439.g003){ref-type="fig"}, and a detailed list of the mapped genes is presented in [S6 Table](#pone.0236439.s008){ref-type="supplementary-material"}. The most prominent cellular components in GO terms ([Fig 3A](#pone.0236439.g003){ref-type="fig"}) were exosomes (GO:0070062), cytoplasm (GO:0005737) and extracellular (GO:0005576) comprising 77.7%, 68.0% and 66.0% of the identified proteins, respectively. The enriched biological process GO terms ([Fig 3B](#pone.0236439.g003){ref-type="fig"}) were cell growth and/or maintenance (GO:0016049) and immune response (GO:0006955), comprising 32.4% and 22.5%, respectively. For the molecular function ([Fig 3C](#pone.0236439.g003){ref-type="fig"}) enriched GO terms were transporter activity (GO:0005215), structural constituent of cytoskeleton (GO:0005200), structural molecule activity (GO:0005198), and complement activity (GO: 0006956) comprising 14.7%, 14.7%, 11.8%, and 10.8% of the identified proteins, respectively.

![Gene ontology enrichment analysis of identified proteins from EVs with two or more unique peptide--containing proteins and p-value ≤0.05 (Holm-Bonferroni corrected) performed with FunRich 2.1.2 software using human genome as a background.\
A) Cellular component enrichment analysis, B) molecular function enrichment analysis, and C) biological process enrichment analysis.](pone.0236439.g003){#pone.0236439.g003}

Of the 138 proteins, 35 showed significant differences in concentration (ANOVA with Kruskall-Wallis test followed by Dunn´s test), between the plasma and serum EV samples ([Table 1](#pone.0236439.t001){ref-type="table"}). The majority of these proteins \[[@pone.0236439.ref021]\] were upregulated in the EVs isolated from serum, 12 proteins in the EVs isolated from EDTA-plasma, and two in the EVs isolated from ACD-plasma. The further analysis of 21 proteins with highest mean in serum EVs revealed enriched molecular function in transporter activity (GO:0005215), including apolipoproteins A1, A2 and C3, transferrin and vitamin D binding protein. Additionally, the EVs displayed differences in the amounts of coagulation and complement proteins, protease inhibitors and different classes of immunoglobulins ([Table 1](#pone.0236439.t001){ref-type="table"}). The most prominent GO term in molecular function of combined EDTA and ACD plasma EVs was protein binding (GO:0005515).

10.1371/journal.pone.0236439.t001

###### Proteins (n = 35) showing significant difference between the plasma and serum EV samples (Anova with Kruskall-Wallis test followed by Dunn´s test, *p*-value ≤ 0.05) are shown.

Five keratins listed here were not excluded although they are considered to originate from exogenous sources such as skin or hair.

![](pone.0236439.t001){#pone.0236439.t001g}

  Kruskall-Wallis                                                                                         
  -------------------------------------------------- ----------- ---------- --------- --------- --------- --
  **Alpha-1-antitrypsin**                            Citrate     21128.5    3673.3    0.174               
  EDTA                                               57249.3     23861.6    0.571     0.054               
  Serum                                              84532.5     5897.2     0.141     0.005\*   0.365     
  **APOC4-APOC2 readthrough (NMD candidate)**        Citrate     2899.5     269.1     0.308               
  EDTA                                               14746.6     3666.4     0.308     0.042\*             
  Serum                                              23054.3     322.9      0.042\*   0.002\*   0.308     
  **Apolipoprotein A-I**                             Citrate     327405.2   26276.5   0.571               
  EDTA                                               763780.0    136205.2   0.174     0.054               
  Serum                                              964279.7    111475.8   0.031\*   0.007\*   0.428     
  **Apolipoprotein A-II**                            Citrate     9432.0     1918.8    0.428               
  EDTA                                               32012.0     10122.1    0.213     0.042\*             
  Serum                                              46145.7     3288.2     0.042\*   0.005\*   0.428     
  **Apolipoprotein C-III**                           Citrate     12313.4    2369.5    0.734               
  EDTA                                               45020.7     29899.0    0.089     0.042\*             
  Serum                                              40119.1     2971.9     0.042\*   0.017\*   0.734     
  **C4b-binding protein beta chain**                 Citrate     32830.5    4683.5    0.308               
  EDTA                                               145233.1    92104.5    0.174     0.017\*             
  Serum                                              129147.1    21501.1    0.089     0.007\*   0.734     
  **Clusterin**                                      Citrate     15921.9    2556.5    0.174               
  EDTA                                               64159.9     2776.6     0.113     0.003\*             
  Serum                                              26015\.     4840.8     1.00      0.174     0.113     
  **Complement C1s subcomponent**                    Citrate     130601.2   18724.9   0.308               
  EDTA                                               77030.6     18048.8    0.042\*   0.308               
  Serum                                              574764.3    80460.7    0.308     0.042\*   0.002\*   
  **Complement factor H**                            Citrate     37145.7    4413.8    0.571               
  EDTA                                               97696.5     24032.5    0.213     0.07                
  Serum                                              161619.3    19798.8    0.024\*   0.005\*   0.308     
  **Extracellular matrix protein 1**                 Citrate     1361.0     349.4     0.910               
  EDTA                                               2848.3      764.6      0.113     0.141               
  Serum                                              7871.9      5854.9     0.009\*   0.013\*   0.3008    
  **Far upstream element-binding protein 2**         Citrate     40731.4    11563.2   0.428               
  EDTA                                               130437.5    10503.6    0.428     0.113               
  Serum                                              272062.8    40803.3    0.042\*   0.005\*   0.213     
  **Fibrinogen alpha chain**                         Citrate     286470.0   80015.7   0.497               
  EDTA                                               1040565.0   140516.8   0.213     0.054               
  Serum                                              178365.8    33284.6    0.089     0.308     0.003\*   
  **Fibrinogen beta chain**                          Citrate     247084.9   82918.2   0.571               
  EDTA                                               796061.9    71036.9    0.213     0.07                
  Serum                                              52282.2     24865.0    0.07      0.213     0.002\*   
  **Fibrinogen gamma chain**                         Citrate     214132.6   59581.7   0.428               
  EDTA                                               681749.2    115693.1   0.428     0.113               
  Serum                                              112276.9    6000.7     0.042\*   0.213     0.005\*   
  **Ficolin-3**                                      Citrate     39691.6    6389.57   0.571               
  EDTA                                               3262480.8   16914469   0.024\*   0.005\*             
  Serum                                              175056.8    89930.4    0.213     0.07      0.308     
  **Haptoglobin-related protein**                    Citrate     72310.9    6719.7    0.005\*             
  EDTA                                               216281.3    208441.5   0.308     0.07                
  Serum                                              121909.9    24163.3    0.174     0.141     0.734     
  **Immunoglobulin heavy variable 5--51**            Citrate     2005.0     146.1     0.089               
  EDTA                                               27441.8     12458.0    0.174     0.002\*             
  Serum                                              3673.2      79.9       0.734     0.174     0.089     
  **Immunoglobulin kappa variable 3--20**            Citrate     23823.5    1779.9    0.571               
  EDTA                                               79664.0     33562.0    0.024\*   0.005\*             
  Serum                                              46655.7     3347.3     0.213     0.07      0.308     
  **Immunoglobulin lambda constant 2**               Citrate     34925.7    9817.4    0.365               
  EDTA                                               90591.5     19342.8    0.365     0.07                
  Serum                                              145174.1    28041.9    0.042\*   0.003\*   0.258     
  **Immunoglobulin lambda constant 7**               Citrate     3043.6     1419.7    0.428               
  EDTA                                               1933.9      501.0      0.213     0.651               
  Serum                                              438.4       349.6      0.007\*   0.054     0.141     
  **Immunoglobulin lambda variable 2--14**           Citrate     11752.6    3612.3    0.910               
  EDTA                                               21819.8     4915.8     0.054     0.07                
  Serum                                              23822.8     8356.2     0.024\*   0.031\*   0.734     
  **Immunoglobulin lambda-like polypeptide 5**       Citrate     67358.0    15634.6   0.428               
  EDTA                                               186777.2    68310.8    0.113     0.017\*             
  Serum                                              164633.0    4839.5     0.089     0.013\*   0.91      
  **Inter-alpha-trypsin inhibitor heavy chain H4**   Citrate     2136.6     130.5     0.910               
  EDTA                                               4742.3      2796.6     0.141     0.113               
  Serum                                              27310.24    1537.1     0.013\*   0.009\*   0.308     
  **Keratin type II cuticular Hb6**                  Citrate     4676.76    1131.9    0.571               
  EDTA                                               226331.9    72476.3    0.005\*   0.024\*             
  Serum                                              9422.9      332.7      0.07      0.231     0.308     
  **Keratin type II cytoskeletal 1b**                Citrate     6686.7     1671.8    0.571               
  EDTA                                               23137.7     6736.6     0.089     0.024\*             
  Serum                                              25899.7     3549.7     0.07      0.017\*   0.91      
  **Keratin type II cytoskeletal 3**                 Citrate     8968.3     1474.3    1.00                
  EDTA                                               16936.0     5221.0     0.571     0.089               
  Serum                                              25805.0     3225.4     0.089     0.005\*   0.258     
  **Keratin type II cytoskeletal 7**                 Citrate     9786.3     5026.1    0.428               
  EDTA                                               28739.1     9806.1     0.428     0.113               
  Serum                                              78335.4     27832.8    0.042\*   0.005\*   0.213     
  **Keratin type II cytoskeletal 75**                Citrate     17435.1    3417.5    0.910               
  EDTA                                               23954.2     5558.9     0.231     0.258               
  Serum                                              39640.8     7021.8     0.013\*   0.017\*   0.213     
  **Mannan-binding lectin serine protease 1**        Citrate     19359.2    838.0     1.00                
  EDTA                                               369877.9    451573.1   0.089     0.005\*             
  Serum                                              82930.6     47213.7    0.308     0.031\*   0.497     
  **NFX1-type zinc finger-containing protein 1**     Citrate     1665.6     406.6     0.258               
  EDTA                                               5768.4      2119.3     0.365     0.042\*             
  Serum                                              9485.0      2649.1     0.07      0.003\*   0.365     
  **Pro-thrombin**                                   Citrate     16532.6    2078.7    0.174               
  EDTA                                               36920.9     16154.9    1.00      0.174               
  Serum                                              92027.3     11207.8    0.113     0.003\*   0.113     
  **Putative uncharacterized protein MYH16**         Citrate     393.4      93.2      0.734               
  EDTA                                               5638.6      2475.0     0.024\*   0.009\*             
  Serum                                              734.2       125.3      0.308     0.174     0.213     
  **Serotransferrin**                                Citrate     246039.8   45043.8   0.428               
  EDTA                                               603798.7    62743.3    0.258     0.054               
  Serum                                              1127260.8   200381.7   0.031\*   0.003\*   0.308\*   
  **Transthyretin**                                  Citrate     850.2      268.5     0.024\*             
  EDTA                                               5663.8      5519.4     1.00      0.024\*             
  Serum                                              1237.8      259.7      0.113     0.497     0.113     
  **Vitamin D-binding protein**                      Citrate     11973.0    1888.2    0.497               
  EDTA                                               43094.2     16511.6    0.258     0.07                
  Serum                                              79524.5     15148.7    0.042\*   0.007\*   0.365     

The proteome of plasma EVs has been reported in several studies and can be obtained from Exocarta \[[@pone.0236439.ref028]\] and EVpedia \[[@pone.0236439.ref029]\]. To understand our results, we performed data comparisons between our results and the results from two other studies which we deemed most relevant by their study design. The study of Kalra et al. compared the proteome of plasma EVs which had been isolated with three different isolation methods: differential ultracentrifugation (dUC), immunoaffinity, and discontinuous gradient ultracentrifugation (DG) \[[@pone.0236439.ref030]\]. This study reported 56 common proteins with our proteome from dUC and DG samples, including complement proteins, immunoglobulins, apolipoproteins and keratins. Similar results have also been reported in studies using dUC \[[@pone.0236439.ref031]--[@pone.0236439.ref034]\] or SEC as isolation method \[[@pone.0236439.ref035]--[@pone.0236439.ref037]\]. In the study of Karimi et al. it was shown that by combining dUC, DG and SEC, it is possible to avoid lipoprotein and soluble protein contamination and to isolate highly purified plasma EVs for proteomic analysis \[[@pone.0236439.ref036]\]. Comparing our 138 proteins from UC-isolated EVs with those of dUC-isolated EVs \[[@pone.0236439.ref030]\] and dUC combined with DG and followed by SEC isolated EVs \[[@pone.0236439.ref036]\] showed that 46 proteins were shared with both of the other data sets, 9 proteins only with Kalra et al. and 53 proteins only with Karimi et al. ([Fig 4](#pone.0236439.g004){ref-type="fig"}).

![Venn diagram of overlapping proteins from a comparison of the proteomic data of our study and two previous studies of proteome of EVs \[[@pone.0236439.ref030], [@pone.0236439.ref036]\].](pone.0236439.g004){#pone.0236439.g004}

Because we found similarities in the EV proteome of our study with these two previous studies, which had used different and more diligent EV isolation procedures, we hypothesized that there may be a shared "EV protein corona". To investigate this hypothesis, we compared our EV proteome to that of NPs, which had been incubated with plasma to generate a protein corona. We compared the list of the 108 proteins which were shared with our study and two previous EV studies, assuming that these proteins belonged to the EV protein corona, to a set of 84 proteins which were shared between two previous NP proteomic studies \[[@pone.0236439.ref022], [@pone.0236439.ref038]\]. Kari et al. used multi-parametric surface plasmon resonance to identify hard and soft protein corona of liposomes *in situ* \[[@pone.0236439.ref038]\], and Weber et al. analyzed the polystyrene NP protein corona after isolation by dUC and asymmetric flow field-flow fractionation \[[@pone.0236439.ref022]\]. In total, 89 of the "EV corona proteins" were identical to those reported to belong to the NP corona proteins (65%; [Fig 5](#pone.0236439.g005){ref-type="fig"}). A gene ontology analysis with the FunRich analysis tool \[[@pone.0236439.ref027]\] using human genome as background enabled us to map 73 proteins (out of the 89 common proteins) for molecular function, cellular component and biological process GO terms ([S6 Table](#pone.0236439.s008){ref-type="supplementary-material"}). The most prominent cellular component GO terms were exosomes (GO:0070062), extracellular (GO:0005576) and cytoplasm (GO: 0005737) comprising 86%, 75% and 63% of the identified proteins, respectively. The enriched biological process GO terms were cell growth and/or maintenance (GO:0016049), immune response (GO:0006955) and transport (GO: 0006810) comprising 32%, 30% and 20%, respectively. For the molecular function enriched GO terms were transporter activity (GO:0005215), structural constituent of cytoskeleton (GO:0005200) and complement activity (GO: 0006956), comprising 20%, 17% and 14% of the identified proteins, respectively.

![Venn diagram comparing the proteomic data of our study to a shared proteome from two previous studies of nanoparticle corona proteins accumulated from plasma \[[@pone.0236439.ref022], [@pone.0236439.ref038]\] showing a set of overlapping proteins, which suggests that a common corona proteome of plasma proteins accumulates on EVs and synthetic particles \[[@pone.0236439.ref022], [@pone.0236439.ref038]\].](pone.0236439.g005){#pone.0236439.g005}

Discussion {#sec017}
==========

At present, blood-derived EVs are a potential source for new biomarkers. Since a blood sample is an *ex vivo* sample, the impact of the pre-analytical choices prior to EV isolation needs to be accounted for to make intelligent use of high-throughput data utilizing samples of large cohorts and biobanks. Therefore, we compared EVs isolated from ACD-, citrate and EDTA-plasma, and serum, to investigate the effects of anticoagulation on the cellular origin and protein composition of the isolated EVs. An early study by George et al. compared large EVs from plasma and serum, and they showed that serum contained more platelet-derived microparticles than ACD plasma \[[@pone.0236439.ref007]\]. Because their study disregarded a large bulk of EVs, we readdressed this issue with contemporary analytical EV methodologies. We showed with four different methods that the serum samples indeed contain a significantly higher concentration of platelet-derived EVs than the plasma samples, and that the serum-derived EVs bound more Annexin V. The number of platelet-derived EVs was also increased in citrate plasma compared to ACD and EDTA, which confirms previous results \[[@pone.0236439.ref039]\]. This suggests that citrate inhibits platelet activation less efficiently than ACD and EDTA, which results in generation platelet-derived EVs in blood samples during and after blood collection, especially if there is a delay between the sample collection and processing. This is significant, because uncontrolled release of platelet-derived EVs affects biomarker discovery, e.g., platelet-derived EVs were shown to skew the miRNA populations in patient and control samples \[[@pone.0236439.ref040]\]. Although the total concentration and size distribution of the plasma-derived EVs were essentially similar between the various anticoagulated plasma and serum samples, a slight difference in the particle numbers was observed between sample sets I and II, where in set II, the concentration of serum-derived EVs was higher than in plasma. This difference may be explained by the variation between the donor pools, and one of the limitations of this study was that the EV analyses could not be associated to the individual donor characteristics such as age or gender So far, very few studies have addressed how such factors impact the EV concentrations in healthy populations \[[@pone.0236439.ref041]--[@pone.0236439.ref043]\]. However, the use of large, well-prepared sample pools enabled us to apply the same material systematically in multiple analyses, strengthening the comparison of the results between analytics.

Ultracentrifugation is still the most used method for EV isolation from plasma (\>60%) or serum (\>55%) reported in EV-TRACK (<http://evtrack.org/>, accessed 20.01.2020), although other methods e.g. SEC and density gradient ultracentrifugation have been adopted. Thus, to mimic the situation with most studies, the isolation of EVs in this study was performed with dUC with one washing step, except Flu-SEC. The use of dUC is another limitation of this study, because dUC is known to co-isolate protein aggregates and lipoproteins \[[@pone.0236439.ref044], [@pone.0236439.ref045]\]. Additionally, the recovery of EVs with dUC is variable (10--80%) and often low \[[@pone.0236439.ref046]\] and it excludes the smallest of EVs and exomeres, to which little attention has been focused so far \[[@pone.0236439.ref047], [@pone.0236439.ref048]\]. Thus, this study did not address the possible alterations in the smallest EV subpopulations.

Several studies of proteomics on plasma and/or serum-derived EVs using various isolation methods have been published \[[@pone.0236439.ref032], [@pone.0236439.ref034]--[@pone.0236439.ref037]\], and regardless of the isolation method, the published EV proteomes show a remarkable similarity. This indicates that certain plasma proteins are tightly bound to the EV surface constituting a true protein corona rather than being mere co-isolating contaminants. The proteome of EVs comprised lipoproteins, immunoglobulins, and coagulation and complement proteins. The presence of several transporter proteins in the protein corona suggests that EV surfaces may have a previously unconsidered role in biomolecule transportation. As the enzymatic removal of the EV surface proteins has been shown to hamper cellular uptake \[[@pone.0236439.ref049], [@pone.0236439.ref050]\], the protein corona may affect the functional properties of EVs. The heterogeneity of the protein corona was shown to affect the hydrodynamic range of EVs, as well as their mobility in solution and extracellular matrix \[[@pone.0236439.ref051]\].

Our proteomics analysis of the albumin-depleted EVs from plasma and serum showed an overlap not only with the previous EV studies \[[@pone.0236439.ref030], [@pone.0236439.ref036]\], but also with NP studies \[[@pone.0236439.ref022], [@pone.0236439.ref038]\]. The NP studies chosen for comparison applied isolation methods asymmetric field flow fractionation and multi-parametric surface plasmon resonance which are considered not to co-isolate soluble proteins, and thereby strengthen the concept that the shared proteins with EVs are unlikely to be co-isolated---artefacts. Of note, in some corona studies NPs added to plasma were isolated by methods which are also used to isolate EVs from plasma and serum \[[@pone.0236439.ref052]--[@pone.0236439.ref056]\]. In such studies, one cannot conclude whether the reported protein corona of NPs originates truly from NPs, from co-isolated EVs, or both. In future studies, this aspect should be taken into account when conducting NP protein corona research, as also noted by a recent viewpoint article \[[@pone.0236439.ref057]\].

The similarities between the shared extravesicular cargo of EVs and NPs imply that both EVs and NPs accumulate a selected plasma protein corona on their surface, which may be applicable to biomarker discovery. Many of the surface-attached proteins of EVs associate with pathological states and thus could be useful for diagnostics. For example, synovial fluid-derived EVs of rheumatic arthritis patients were shown to carry complement factors and complement activator molecules \[[@pone.0236439.ref058]\], and the adhered protein composition of EVs was shown to reflect the disease state in preeclampsia \[[@pone.0236439.ref059]\].

To our knowledge, this is the first study highlighting the importance of the EV corona. To conclude, we state that plasma obtained with different anticoagulant and/or serum should not be mixed as a source of EVs for biomarker discovery. This is particularly relevant for clinical studies and biobank samples. Secondly, an enrichment of platelet-derived EVs from serum samples may offer new opportunities to study platelet-associated pathologies. Thirdly, the comparison of proteomic studies suggests that EVs have a protein corona that includes both soft and hard coronas offering an interactive surface with biological membranes, which may offer novel insights in the pathophysiological roles of EVs. Since the investigations on the communicasome role of EVs have so far predominantly concentrated on the intravesicular cargo and regarded the corona proteins simply as contaminants, we suggest that this "piggyback" cargo should be re-evaluated. We expect our study to pave a way for more discoveries regarding the role of the extracellular cargo of EVs.
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4\. Provide data table or representative NTA plots of size distributions for visual assessment of the size distribution differences instead of referring "data not shown" on line 215. This data could be included in the Supplementary Information document.

5\. The statement "The generally upheld view of the EV field is that there are more platelet-derived "microparticles" or EVs, in serum than plasma," on line 240 seems too subjective and needs a published reference. The sentence should be rephrased to more scientifically covey its meaning. The authors could instead write something similar as in the discussion section lines 348-349, e.g., "The fact that large EVs from serum have been shown to contain more platelet-derived microparticles than large EV from ACD plasma (7), prompted us to..."

6\. Quality of all figures is unacceptably low. Replace figures with higher resolution versions.

7\. Table 1 should go to Supplementary Information and columns ACD, Citrate, and EDTA clearly marked as P values.

8\. The word "blotted" on line 275 should read "plotted".

9\. The statement: "At the moment, very few studies have addressed the factors (age, sex) which may affect EV concentrations in healthy populations", on lines 362-363, requires citation(s) of some of the referenced studies.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Richard Pratley, MD

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0236439.r002
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Response to reviewers

Reviewer \#1: Extracellular vesicles (EVs) have been extensively used for biomarker studies. It is expected that preanalytical processing methods of freshly draw blood may affect components of EV cargo. So far, however, few studies have evaluated such effect. To address this question, in this paper, Palviainen et al examined effect of anti-coagulation on isolated EV population and found significant increase on EV counts in serum when compared to plasma samples. Proteomics analysis showed significant differences between serum and plasma as well as among plasma samples with different anticoagulants. Results from the study enriches our knowledge on the effect of blood sample preparation methods on isolated EV characteristics. The manuscript is well-written, and the data are solid. It can be further improved by addressing the following questions:

We would like to thank the reviewer for his or her positive remarks.

1\. The study mainly focused on difference. It will be beneficial to include scatter plots showing similarity (with r values) in commonly detected proteins.

We thank the reviewer for this valuable comment. We have performed Pearson correlation analysis (as described in Methods lines 199-200), and results are presented in Results (lines 284-286) and Supplementary files (S5 table).

2\. Please provide a supplementary table showing proteomics data categorized by sample types (serum, different anticoagulants).

We have now added the proteomics file as a Supplementary file (S4 table).

3\. Keratin proteins are likely from contamination during sample preparation. A discussion on its origination should be added.

We agree that the majority of the identified keratins likely originate from exogenous sources, and this information has been added to the Legend text of Table 1.

4\. Discussion on limitation of the study should be added.

We thank the reviewer for this valuable comment. We have now included the following limitations to the Discussion: the use of pooled samples, the use of differential ultracentrifugation, and the absence of analysis of the impact of the anticoagulation on the smallest EV. The comments have been integrated in the text and therefore the Discussion had to be rewritten and restructured to reorganize the text. The additions are highlighted.

5\. Figures are in bad quality in pdf file. High resolution in published manuscript is needed.

We wholly agree with both reviewers. The cause is the PDF-generating system of the journal, which produces low-resolution files. All figures accessible through the separate downloadable link were and still are in high resolution. We have now rechecked that all the figures meet the requirements of the journal.

 

Reviewer \#2: Palviainen and colleagues have conducted an interesting and useful work assessing how several anticoagulation reagents for plasma preparation and serum affect the concentration, cellular origin, and protein content of circulating extracellular vesicles (EV). The authors additionally and originally assessed, at least through bioinformatic methods, whether the detected protein cargo could include an EV protein signature resembling a reported protein corona from synthetic nanoparticles. The study is rigorous in its design, using state-of-the-art methods and it is clearly presented. However, there are several issues that need to be addressed to reach publication quality.

Major Issues:

1\. The Statistical Analysis section (and statistical references throughout other items of the Materials and Methods section) needs major improvement. The authors need to clarify how they assessed the normality of the data before implementing ANOVA followed by Tukey tests, which assume normally distributed data. The statement "For multiple parameter analysis of non-normal distributed data Tukey multiple comparison test was used", on line 194, is not accurate. What the authors need to do to handle comparisons of multiple groups of non-normal data is a transformation of the data to approximate normality before conducting an ANOVA test followed by the post-hoc Tukey test for multiple comparisons, or, alternatively, the implementation of a non-parametric test such as the Kruskal-Wallis test followed by appropriate post-hoc analysis such as the Dunn test. Additionally, information on the PCA approach is necessary.

We thank the reviewer for the comment and valuable suggestions. Accordingly, we have now tested the data of all experiments for normality using Saphiro-Wilk test, and based on the results analyzed the data of flu-SEC experiment with Tukey test, and the flow cytometry and proteomics data using Kruskall-Wallis test. The statistics-paragraph in the methods has been rephrased based on these changes (lines 192-201). In addition, PCA is now explained in more detail (lines 277-284).

Based on the new statistical analysis of proteomic data done with Kruskall-Wallis test followed by Dunn test (post-hoc), the results were slightly changed. 35 proteins showed significant difference between different sample types and this has now stated in lines 306-314) and table 1 has been now corrected accordingly.

2\. Starting on page 18 of the result section "Protein cargo of the EV corona is modified by anticoagulation or its absence", the authors described several comparisons with lists of proteins from published studies and claim (e.g., on line 322) that the overlap denote "marked similarities regarding the EV proteome". For this claim to be justified, the statistical significance of the overlap between the different studies needs to be assessed. This can be done by calculating an empirical P value for the overlap among the protein lists based on simulation analyses. The simulation analysis would assess the probability of producing an equivalent random overlap between the published MP corona protein signatures (from the published studies) and a number of simulated protein lists (e.g., 1,000 or 10,000 simulated lists) that are generated by randomly selecting lists of proteins from Exocarta or EVpedia (with the simulated protein lists having the same length as the lists of experimentally detected EV proteins in this study). Only then could the overlap be claimed to be significant. The simulation analysis will reveal whether the detected overlap among the lists could have just happened by chance, therefore potentially not meaningful.

We thank the reviewer for the insightful comment and advice concerning performing a simulation analysis. Firstly, we would like to point out that by the chosen wording (e.g. "markedly" in the Abstract) we tried to highlight the novelty, but not statistical significance of our finding as this was the first report on the similarities of EVs and NPs that we are aware of. However, we looked into this suggestion and consulted the experts available to us. Although we agree that a simulation would be very interesting to perform, we feel that in the scope of the current study it is too extensive and difficult for us to do without experience and absence of help on the matter. We also find that the databases on EVs are not well-curated regarding the experimental methods (e.g. EV isolation), so comparison against a randomly produced datasets of very variable studies are likely not be meaningful. Therefore, based on the reviewer's comment, we moderated our text as follows:

•the sentence in line 334-336 as following: "Based on the similarities of the EV proteome of our study and the two earlier studies using different isolation procedures, we hypothesize that there may be a common "EV protein corona".

•the sentence in lines 399-400 was adjusted and the word "remarkable" was removed.

•in the Abstract "markedly" was removed, and the sentence now reads: "Comparison to other studies further revealed that the shared EV protein composition resembles the "protein corona" of synthetic nanoparticles incubated in plasma or serum."

Finally, we were glad to discover a supporting publication from Simonsen and Münter, which was published while our work was being reviewed, which shares our concern about the similarities of NPs and EVs including the protein cargo they carry. "Pay attention to the biological nanoparticles when studying the protein corona on nanomedicines" (<https://onlinelibrary.wiley.com/doi/abs/10.1002/anie.202004611>). Although, the authors did not provide experimental data, we added this reference into the manuscript in the text (lines 406-407).

Minor Issues:

1\. On line 90, the word "each" is misplaced.

The word has been removed.

2\. Methods for EV isolation need to be better described. It is not clear what was the initial volume of pooled plasma or serum used for set I and II (the pellets of which were resuspended in 250 uL of PBS). It is not clear whether the elution from the SEC column was performed as a single elution step with 1 mL of PBS or whether there were multiple fractions collected.

The information on initial volumes of pooled samples for sets I and II is now added to the S1 table (workflow).

The elution from the SEC column was performed as a single elution step with 1 mL PBS. Column geometry and elution protocol was adapted from the application notes of PD MidiTrap G-25 columns (GE Healthcare), except that the stationary phase was replaced from Sephadex G-25 to Sepharose CL-2B. This protocol enables the separation of EVs from soluble proteins (e.g. albumin), but does not separate all lipoprotein particles. This has now been clarified in the manuscript (line 126).

3\. Supplementary Figure 1 should be moved to the main text and significant digits used on Sup. Fig. 1A should be consistent.

S1 figure has now been corrected, but in our opinion the S1 figure serves its purpose for providing visual data of background data of the experiment best in the supplementary files.

4\. Provide data table or representative NTA plots of size distributions for visual assessment of the size distribution differences instead of referring "data not shown" on line 215. This data could be included in the Supplementary Information document.

A Figure depicting size distributions has now been added to S1 figure (C) and the sentence in lines 218-221 has been corrected accordingly.

5\. The statement "The generally upheld view of the EV field is that there are more platelet-derived "microparticles" or EVs, in serum than plasma," on line 240 seems too subjective and needs a published reference. The sentence should be rephrased to more scientifically covey its meaning. The authors could instead write something similar as in the discussion section lines 348-349, e.g., "The fact that large EVs from serum have been shown to contain more platelet-derived microparticles than large EV from ACD plasma (7), prompted us to..."

We thank the reviewer for this suggestion. The sentence has now been edited (lines 243-244).

6\. Quality of all figures is unacceptably low. Replace figures with higher resolution versions.

Unfortunately, the PDF-file that the journal automatically creates contains a low-resolution version of the figures. All the figures were downloadable in high resolution format for the review from a separate toggle. We have rechecked and all figures meet the requirements of the journal.

7\. Table 1 should go to Supplementary Information and columns ACD, Citrate, and EDTA clearly marked as P values.

We are happy to remove the Table to Supplementary files if the reviewer insists that this will improve the paper. However, we would prefer to keep it in the main text, so that the information of the corona proteins would be easily accessible to the readers, which is not the case with separate supplementary information which is often accessed only a few people. We would like the readers to reflect on the meaning and impact of the selection of the corona proteins on EVs. Table 1 has been corrected after the new statistical analysis with Kruskall-Wallis test followed with Dunn´s test. As reviewer has suggested, the columns ACD, Citrate and Serum has now been marked with "p-value".

8\. The word "blotted" on line 275 should read "plotted".

Corrected

9\. The statement: "At the moment, very few studies have addressed the factors (age, sex) which may affect EV concentrations in healthy populations", on lines 362-363, requires citation(s) of some of the referenced studies.

We have added three references (lines 375-380): Eitan et al., Age-related changes in plasma extracellular vesicle characteristics and internalization by leukocytes. Scientific Reports 2017, Arraud et al., Extracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration. Journal of thrombosis and haemostasis 2014, and Frühbeis et al., Physical exercise induces rapid release of small extracellular vesicles into the circulation. Journal of extracellular vesicles 2015.
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PONE-D-20-08075R1

Dear Dr. Siljander,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

John Matthew Koomen, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have satisfactorily addressed my comments. The data presented will fill some knowledge gap in EV research.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: **Yes: **Liang Wang

Reviewer \#2: **Yes: **Richard Pratley, MD

10.1371/journal.pone.0236439.r004
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Extracellular vesicles from human plasma and serum are carriers of extravesicular cargo ─ implications for biomarker discovery

Dear Dr. Siljander:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. John Matthew Koomen

Academic Editor

PLOS ONE
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